Q-omics provides the consensus-scored UAP1 profile across patient tissues and cancer cell-line models. UAP1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, UAP1 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, UAP1 protein abundance shows 29,583 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, LUAD, and LSCC as cancer lineages where UAP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UAP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UAP1 survival associations across molecular data types. UAP1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UAP1 RNA expression–survival associations across cancer types. High UAP1 expression shows unfavorable associations in KIRP, ACC, UVM, LGG, HNSC and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for UAP1 RNA expression.
This table summarizes UAP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 12. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UAP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UAP1 shows lower tumor expression in COAD, KIRP and READ and higher tumor expression in LUAD, BRCA and LUSC. The LUAD box plot shows higher UAP1 RNA expression in tumor versus normal tissue (log2 FC = +1.065, t-test p < 0.001).
This table shows molecular features associated with UAP1 in patient tissues and cancer cell lines. In patient samples, UAP1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, UAP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
